INS and heart failure: Consistent with a higher comorbidity burden, patients with CHA2DS2-VASc ≥4 also more often received statins, acetylsalicylic acid, metformin and insulin, aligning with prior observations that polypharmacy in heart-failure care tracks with cardiometabolic multimorbidity (40, 41).